Takeda Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Takeda Pharmaceutical has a total shareholder equity of ¥6,742.6B and total debt of ¥4,664.2B, which brings its debt-to-equity ratio to 69.2%. Its total assets and total liabilities are ¥14,222.9B and ¥7,480.3B respectively. Takeda Pharmaceutical's EBIT is ¥579.2B making its interest coverage ratio 3.6. It has cash and short-term investments of ¥288.4B.
Key information
69.2%
Debt to equity ratio
JP¥4.66t
Debt
Interest coverage ratio | 3.6x |
Cash | JP¥288.36b |
Equity | JP¥6.74t |
Total liabilities | JP¥7.48t |
Total assets | JP¥14.22t |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: TKPH.F's short term assets (¥2,428.8B) exceed its short term liabilities (¥2,282.2B).
Long Term Liabilities: TKPH.F's short term assets (¥2,428.8B) do not cover its long term liabilities (¥5,198.2B).
Debt to Equity History and Analysis
Debt Level: TKPH.F's net debt to equity ratio (64.9%) is considered high.
Reducing Debt: TKPH.F's debt to equity ratio has reduced from 124.8% to 69.2% over the past 5 years.
Debt Coverage: TKPH.F's debt is not well covered by operating cash flow (15.7%).
Interest Coverage: TKPH.F's interest payments on its debt are well covered by EBIT (3.6x coverage).